Adverse Drug Reaction
Alemtuzumab immunotherapy reactivates hepatitis B virus infection
Published in Blood Weekly, April 14th, 2005
"Reactivation of hepatitis B virus (HBV) infection in subjects receiving cytotoxic treatment for hematological malignancies occurs in 21%-53% of chronic hepatitis B surface antigen (HBsAg) carriers and in an unknown number of HBsAg negative subjects harboring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocyte cells produces deep immunosuppression," according to researchers in Italy.
"We describe two subjects with chronic lymphocytic leukemia and occult HBV infection who developed a virological and biochemical flare...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-04-14)
More Articles from Blood Weekly
- Blood Cell Substitute
Liposomes encapsulating hemoglobin evaluated as a red blood cell substitute - Leukapheresis
SC mobilization influences CD34+ cell collection efficiency of leukapheresis - Stem Cell Transplantation
Cord blood better than haploidentical mobilized PBL for sustained engraftment - Tissue Engineering
Fiber-based tissue engineered scaffold designed for ligament replacement - Tissue Engineering
Hydrogel scaffold developed for cell adhesion and neural outgrowth - Adult T-Cell Leukemia
TSLC1 overexpression may be a molecular marker for acute-type ATL - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
